


BEV



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 926 137 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

30.06.1999 Bulletin 1999/26

(51) Int Cl⁶ C07D 213/79, C07D 213/81,
C07D 213/84, C07D 401/04,
A61K 31/44, C12P 17/12

(21) Application number: 98308860.0

(22) Date of filing: 29.10.1998

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 04.11.1997 WOPCT/CA97/01383

(83) Declaration under Rule 28(4) EPC (expert solution)

(71) Applicant: PFIZER INC.
New York, N.Y. 10017 (US)

(72) Inventors:


- Hirai, Hideo, Pfizer Pharm. Inc.,
Cen. Res. Nagoya
Chita-gun, Aichi-ken 470-2393 (JP)

- Ichikawa, Katsuomi, Pfizer Pharm. Inc.
Chita-gun, Aichi-ken 470-2393 (JP)
- Kojima, Nakao, Pfizer Pharm. Inc.
Chita-gun, Aichi-ken 470-2393 (JP)
- Nishida, Hiroyuki, Pfizer Pharm. Inc.
Chita-gun, Aichi-ken 470-2393 (JP)
- Satake, Kunio, Pfizer Pharm. Inc.
Chita-gun, Aichi-ken 470-2393 (JP)
- Yoshikawa, Nobuji, Pfizer Pharm. Inc.
Chita-gun, Aichi-ken 470-2393 (JP)

(74) Representative: Hayles, James Richard
Pfizer Limited,
Patents Department,
Ramsgate Road
Sandwich Kent CT13 9NJ (GB)

(54) Picolin acid derivatives useful in the treatment of IL-1 and TNF mediated diseases

(57) The present invention provides novel 5-substituted picolinic acid compounds of formula (I) or a pharmaceutically acceptable salt thereof:



wherein R¹ and R² are independently H, C₂-C₆ acyl or halo-substituted benzoyl; and R³ is -C(O)O-C₁-C₆ alkyl, C(O)OH, CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole, with the proviso that when R₂ is acetyl and R³ is methoxycarbonyl, R¹ is not H; and that when R³ is CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole, R¹ and R² are H.

The present invention also relates to a pharmaceutical composition comprising compound of the present invention, which is useful in the treatment of IL-1 and TNF mediated diseases or the like.

The present invention further relates to a process for producing the compounds of the formula (I).

EP 0 926 137 A1

Description**Technical Field**

5 [0001] This invention relates to novel 5-substituted picolinic acid compounds, and particularly to novel 5-substituted picolinic acid compounds produced by fermentation of a fungus *Marasmiellus sp.*, which has been deposited as FERM BP-5735. This invention also relates to processes for producing the 5-substituted picolinic acid compounds, and a pharmaceutical composition comprising the same, which is useful in the treatment of IL-1 and TNF mediated diseases

Background Art

[0002] Interleukin-1 (IL-1) and tumor necrosis factor (TNF) are biological substances produced by a variety of cells, such as monocytes or macrophages. IL-1 and TNF have been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation.

15 [0003] There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Recent evidence also

20 links IL-1 activity to diabetes (T. Mandrup-Poulsen et al., *Allergy*, 1985, 40, 424). The only IL-1 blocker available today is the natural IL-1 receptor antagonist (IL-1RA), which is easily metabolized in the bloodstream with a very short half-life (E. V. Granowitz et al., *Cytokine*, 1992, 4, 353). Thus, active research has been carried out to develop stable, long-acting agents which can be taken by oral administration or by parenteral injections rather than by intravenous infusion, which is required for IL-1RA. A number of compounds as IL-1 receptor antagonists, IL-1 biosynthesis inhibitors, and

25 IL-1 converting enzyme inhibitors have been known (C. C. George et al., *Exp. Opin. Ther. Paten*; 1996, 6 (1), 41).

[0004] Excessive or unregulated TNF production has also been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption

30 diseases, reperfusion injury, acquired immunodeficiency syndrome (AIDS), AIDS related complex (ARC), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis. Although significant progress in developing potent TNF modulators has been achieved through the use of recombinantly derived proteins including monoclonal antibodies and soluble receptors, the development of biosynthesis inhibitors and receptor antagonists has been less successful. Recently a number of small molecule TNF modulators have been claimed. Most of them which specifically

35 inhibit TNF production do so by increasing intracellular cyclic adenosine monophosphate (cAMP) which ultimately blocks TNF gene expression (Y. KATAKAMI et al., *Immunology*, 1988, 64, 719). The most important of these compounds are the rolipram and pentoxifylline-related phosphodiesterase IV (PDE IV) inhibitors which are being pursued by a number of pharmaceutical companies (A. BADGER et al., *Circul. Shock*, 1994, 44, 188). The ability of thalidomide to block TNF production contributes to its therapeutic properties in humans (E. P. SAMPAIO et al., *J. Exp. Med.*, 1991, 73, 699). Recent studies suggest that cell-associated TNF may be necessary for normal host defense mechanisms

40 This finding has added to the excitement concerning the identification of a unique metalloproteinase enzyme which is responsible for the proteolytic processing of TNF. Inhibitors of matrix metalloproteinase-related enzymes have appeared (K. M. MOHLER et al., *Nature*, 1994, 370, 218).

[0005] Inhibitors of interleukin 1, 6 and 8 and TNF are described in PCT application US94/07969 which was published

45 on Jan. 26 1995. The inhibitors of TNF are also described in PCT application US94/04950 which was published on Nov. 24 1994. Substituted picolinic acid compounds have been known to be produced by fungus. These include phenopicolinic acid (5-(4-hydroxybenzyl)picolinic acid) (T. Nakamura et al., *J. Antibiotics*, 27:477-, 1975), fusaric acid (5-butylicpicolinic acid) (H. Hidaka et al., *J. Antibiotics*, 22:228-, 1969), and fusarinolic acid (K. Steiner et al., *Helv. Chim. Acta*, 54:845-, 1971).


50 [0006] The object of the present invention is to provide novel 5-substituted picolinic acid compounds having an excellent activities for TNF and/or IL-1 biosynthesis inhibition and a pharmaceutically composition comprising the same. Another object is to provide processes for producing the novel 5-substituted picolinic acid compounds.

Brief Disclosure of the Invention

55

[0007] Accordingly, the present invention provides novel 5-substituted picolinic acid compounds of formula (I):

5



or a pharmaceutically acceptable salt thereof.

- 10 wherein R¹ and R² are independently H, C₂-C₆ acyl or halo-substituted benzoyl; and R³ is -C(O)O-C₁-C₆ alkyl, C(O)OH, CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole, with the proviso that when R² is acetyl and R³ is methoxycarbonyl, R¹ is not H; and that when R³ is CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole, R¹ and R² are H.

15 [0008] Preferred compounds of this invention are those of formula (I) shown above, wherein R³ is -C(O)O-C₁-C₆ alkyl or C(O)OH, with the proviso that when R² is acetyl and R³ is methoxycarbonyl, R¹ is not H.

[0009] The present invention also provides a culture of *Marasmiellus* sp. FERM BP-5735, which is capable of producing the 5-substituted picolinic acid compounds, especially those of formula (I) wherein R¹ and R² are H, and R³ is methoxycarbonyl (methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate), or R¹ is acetyl, R² is H, and R³ is methoxycarbonyl (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate).

20 [0010] Further, the present invention provides a process for producing the 5-substituted picolinic acid compounds of formula (I), which comprises cultivating a microorganism having identifying characteristics of *Marasmiellus* sp., FERM BP-5735, or a mutant or recombinant form thereof.

[0011] The present invention further provides a process comprising additional steps of isolating the 5-substituted picolinic acid compounds from the fermentation broth and chemically modifying the isolated compounds.

25 [0012] Also, the present invention provides a pharmaceutical composition for use in the treatment of IL-1 and/or TNF mediated diseases, which comprises the 5-substituted picolinic acid compounds of formula (I) wherein R¹ and R² are H; and R³ is methoxycarbonyl (methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate); R¹ is acetyl, R² is H; and R³ is methoxycarbonyl (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate). R¹ and R² are H, and R³ is C(O)OH (5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid); or R¹ and R² are acetyl; and R³ is methoxycarbonyl (methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate), or pharmaceutically acceptable salt thereof in an amount effective in such treatments, and a pharmaceutically acceptable carrier.

30 [0013] Also, the present invention provides a method for the treatment of IL-1 and/or TNF mediated diseases, which comprises administering to said subject an antiinflammation amount of the compound of formula (I) wherein R¹ and R² are H; and R³ is methoxycarbonyl (methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate); R¹ is acetyl; R² is H, and R³ is methoxycarbonyl (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate). R¹ and R² are H; and R³ is C(O)OH (5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid); or R¹ and R² are acetyl; and R³ is methoxycarbonyl (methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate); and a pharmaceutically acceptable carrier.

Detailed Description of the Invention

40 [0014] The microorganism used in this invention is a strain of *Marasmiellus* sp. which was identified by and obtained from University of Tennessee. It was deposited by Pfizer Pharmaceuticals Inc. of Mitsui Building, 1-1, Nishi-shinjuku 2-chome, Shinjuku-ku, Tokyo 163, Japan under the accession number FERM BP-5735 at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (located at 1-3 Higashi 1-chome, Tsukuba, Ibaraki 305, Japan) under the Budapest Treaty on October 29, 1996. The taxonomical properties of the genus *Marasmiellus* have been reported by Singer, R. (in *The Agaricales in modern taxonomy*, 320-328, 1986).

45 [0015] In this invention, a mutant or recombinant form of FERM BP-5735 having the ability to produce the novel 5-substituted picolinic acid compounds of formula (I) can be also used. The mutant or recombinant form may be obtained by spontaneous mutation, artificial mutation with ultraviolet radiation, or treatment with mutagen such as N-methyl-N-nitro-N-nitrosoguanidine or ethyl methanesulfonate, or a cell technology method such as protoplast fusion, gene manipulation or the like, according to well-known methods.

50 [0016] According to the present invention, the novel 5-substituted picolinic acid compounds of formula (I) may be produced by aerobic fermentation of FERM BP-5735, or a mutant or recombinant form thereof, under conditions similar to those generally employed to produce bioactive compounds by fermentation.

55 [0017] FERM BP-5735, or a mutant or recombinant form thereof, is usually fermented under submerged aerobic conditions with agitation at a temperature of 20 to 40°C for 1 to 20 days, which may be varied according to fermentation conditions. Cultivation of FERM BP-5735 to produce said 5-substituted picolinic acid compounds of formula (I) preferably takes place in aqueous nutrient media at a temperature of 25 to 35°C for 10 to 15 days. The pH of medium may

be adjusted in the range from 4.0 to 9.0, preferably from 5.5 to 7.0.

[0018] Nutrient media useful for fermentation include a source of assimilable carbon such as sugars, starches and glycerol; a source of organic nitrogen such as casein, enzymatic digest of casein, soybean meal, cotton seed meal, peanut meal, wheat gluten, soy flour, meal extract and fish meal; a source of growth substances such as mineral salts, sodium chloride and calcium carbonate; and trace elements such as iron, magnesium, copper, zinc, cobalt and manganese. If excessive foaming is encountered during fermentation, antifoam agents such as polypropylene glycols or silicones may be added to the fermentation medium.

[0019] Aeration of the medium in fermentors for submerged growth is maintained at 10 to 200%, preferably at 50 to 150% volumes of sterile air per volume of the medium per minutes. The rate of agitation depends on the type of agitator employed. A shake flask is usually run at 150 to 250 rpm whereas a fermentor is usually run at 300 to 2,000 rpm. Aseptic conditions must, of course, be maintained through the transfer of the organism and throughout its growth.

[0020] The 5-substituted picolinic acid compounds thus produced may be isolated by standard techniques such as extraction and various chromatographic techniques.

[0021] As 5-substituted picolinic acid compounds of this invention, a compound of formula (I) wherein R¹ and R² are H, and R³ is methoxycarbonyl (methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate); and a compound of formula (I) wherein R¹ is acetyl, R² is H, and R³ is methoxycarbonyl (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate) were isolated in a substantially pure form from the fermentation mixture. As 5-substituted picolinic acid compounds of this invention, there were synthesized 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid, methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate, methyl 5-(1,2-di-p-bromobenzoyloxypropyl)-2-pyridinecarboxylate, 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide, 5-(1,2-dihydroxypropyl)-N,N-dimethyl-2-pyridinecarboxamide, 5-(1,2-dihydroxypropyl)-2-pyridinecarbonitrile, 5-(1,2-dihydroxypropyl)-2-(2-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine and 5-(1,2-dihydroxypropyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine from methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate by chemical modification. These compounds were identified by various spectroscopic techniques such as UV spectrophotometry, NMR and mass spectrometry, and the results will be shown in the section for working examples.

[0022] The compounds of formula (I) wherein R¹ and R² are an acyl group can be prepared by acylation of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate, and the compounds of formula (I) wherein R³ is alkoxy carbonyl can be prepared by alkylation of demethyl methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate using suitable acylation and alkylating agents under suitable conditions known to those skilled in the art.

[0023] Preferred compounds of this invention include those of formula (I), wherein

R¹ and R² are H; and R³ is methoxycarbonyl (methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate);
R¹ is acetyl; R² is H; and R³ is methoxycarbonyl (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate);
R¹ and R² are H; and R³ is C(O)OH (5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid);
R¹ and R² are acetyl; and R³ is methoxycarbonyl (methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate); and
R¹ and R² are p-bromobenzoyl, and R³ is methoxycarbonyl (methyl 5-(1,2-di-p-bromobenzoyloxypropyl)-2-pyridinecarboxylate).

[0024] Preferred compounds of this invention also include those of the formula (I), wherein

R¹ and R² are H, and R³ is CN(5-(1,2-dihydroxypropyl)-2-pyridinecarbonitrile);
R¹ and R² are H, and R³ is CONH₂ (5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide);
R¹ and R² are H, and R³ is CONHCH₃ (5-(1,2-dihydroxypropyl)-N-methyl-2-pyridinecarboxamide);
R¹ and R² are H, and R³ is CON(CH₃)₂ (5-(1,2-dihydroxypropyl)-N,N-dimethyl-2-pyridinecarboxamide);
R¹ and R² are H, and R³ is 1-methyltetrazole (5-(1,2-dihydroxypropyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine); and
R¹ and R² are H, and R³ is 2-methyltetrazole (5-(1,2-dihydroxypropyl)-2-(2-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine).

[0025] More preferred compounds include a compound of formula (I), wherein

R¹ and R² are H, and R³ is methoxycarbonyl (methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate);
R¹ is acetyl; R² is H; and R³ is methoxycarbonyl (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate);
R¹ and R² are H; and R³ is C(O)OH (5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid); and
R¹ and R² are acetyl; and R³ is methoxycarbonyl (methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate).

[0026] Further preferred compounds of this invention also include those of formula (I) wherein

R¹ and R² are H, R³ is CONH₂ (5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide)

- R¹ and R² are H, R³ is CON(CH₃)₂ (5-(1,2-dihydroxypropyl)-N,N-dimethyl-2-pyridinecarboxamide)
 R¹ and R² are H, R³ is CN (5-(1,2-dihydroxypropyl)-2-pyridinecarbonitrile)
 R¹ and R² are H, R³ is 1-methyltetrazole (5-(1,2-di-hydroxypropyl)-2-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridine)
 and
 5 R¹ and R² are H, R³ is 2-methyltetrazole (5-(1,2-di-hydroxypropyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine)

[0027] The IL-1 and TNF biosynthesis inhibitory activities of the above-mentioned 5-substituted picolinic acid compounds, methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate, (methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate, 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid, methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate, 5-(1,2-di-p-bromobenzoyloxypropyl)-2-pyridinecarboxylate, 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide, 5-(1,2-dihydroxypropyl)-2-pyridinecarbonitrile, 5-(1,2-dihydroxypropyl)-2-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridine and 5-(1,2-dihydroxypropyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine), were measured by the standard *in vitro* protocol described below. These compounds were found to have the IL-1 and TNF biosynthesis inhibitory activities.

15 **TNF bioassay**

[0028] Heparinised human whole blood diluted four-fold with RPMI medium was incubated with 10 µg/ml of Lipopolysaccharide (LPS) in the presence of various concentrations of samples at 37 °C in a humidified atmosphere containing 20 5% CO₂ for 4 h. The TNF titer in the supernatants was determined with L929 cells which were destroyed by TNF quantitatively. L929 cells (2.5 x 10⁴ cells) in 90 µl of E-MEM medium containing 1% fetal calf serum and 0.5 µg/ml of actinomycin D were placed in wells of 96-well microplates (flat-bottom). Ten µl of the supernatants was added to each well and incubated at 37 °C in a humidified atmosphere containing 5% CO₂. After 18 h, the plates were rinsed with 0.9% sterile saline and stained for 10 min with 0.4% crystal violet in MeOH. The plates were washed with distilled water 25 and were dried by air. Fifty µl of methanol was added to each well to elute the crystal violet, and the plates were read on a microplate reader (model 3550, BIO-RAD) at 595 nm. TNF production inhibitory activity is calculated by the formula:

$$30 \text{ Inhibition (\%)} = \left\{ 1 - \frac{[A_{595} \text{ Sample} - A_{595} \text{ Blank}]}{[A_{595} \text{ Control} - A_{595} \text{ Blank}]} \right\} \times 100$$

35 **IL-1 bioassay**

[0029] The supernatants prepared by the same method as TNF bioassay were analyzed IL-1 titer by commercially available specific ELISA system. The plates were read on a microplate reader (model 3550, BIO-RAD) at 490 nm. IL-1 production inhibitory activity is calculated by the formula:

$$40 \text{ Inhibition (\%)} = \left\{ 1 - \frac{[A_{490} \text{ Sample} - A_{490} \text{ Blank}]}{[A_{490} \text{ Control} - A_{490} \text{ Blank}]} \right\} \times 100$$

45 [0030] The pharmaceutically acceptable salts of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate, methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate, 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid, methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate and methyl 5-(1,2-di-p-bromobenzoyloxypropyl)-2-pyridinecarboxylate are prepared in a conventional manner by treating a solution or suspension of the compound with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts.

Administration

55 [0031] The 5-substituted picolinic acid compounds of formula (I) a pharmaceutically acceptable salt are useful in the treatment of inflammation or the like. The 5-substituted picolinic acid compounds of formula (I) and a pharmaceutically acceptable salt may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and

various organic solvents. The pharmaceutical compositions formed by combining the 5-substituted picolinic acid compounds of formula (I) and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredients therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

[0032] For parenteral administration, solutions of the 5-substituted picolinic acid compounds of formula (I) and a pharmaceutically acceptable salt in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

[0033] Additionally, the 5-substituted picolinic acid compounds of formula (I) and a pharmaceutically acceptable salt may be administered topically when treating conditions of the skin and this may be done by way of creams, jellies, gels, pastes, and ointments, in accordance with standard pharmaceutical practice.

[0034] In general, the 5-substituted picolinic acid compounds of formula (I) or its pharmaceutically acceptable salt are present in the above dosage forms at concentration levels ranging 5 to 70 % by weight, preferably 10 to 50% by weight.

[0035] In general, a therapeutically effective daily dose for the active compound will range from 0.01 to 100 mg/kg, generally from about 1 to about 5 mg/kg. As is generally known, the effective dosage for the active compound depends on the intended route of administration and other factors such as age and weight of the patient, as generally known to a physician. The dosage also depends on the illness to be treated.

Examples

[0036] The present invention is illustrated by the following examples. However, it should be understood that the invention is not limited to the specific details of these examples. Spectral and physico-chemical data were obtained on the following instruments: IR, Shimadzu IR-470; UV, JASCO Ubest-30; Optical rotations, JASCO DIP-370 with a 5 cm cell; NMR, JEOL JNM-GX270 equipped with a LSI-11/73 host computer, TH-5 tunable probe and version 1.6 software; EI-MS, Hitachi M-80 with a direct inlet module; and FAB-MS, JEOL JMS-700. The peak shapes are denoted as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). FAB-MS spectra were measured using glycerol matrix.

Example One

Fermentation of *Marasmiellus* sp. (FERM BP-5735)

[0037] Cells from a 10- to 21-day-old petri dish of *Marasmiellus* sp. FERM BP-5735 grown on malt agar medium (malt extract 2.5% and agar 1.5%) were harvested and suspended in 2 ml sterile water. This suspension was used to inoculate two 500-ml flasks containing 100 ml of Medium-1 (glucose 2%, malt extract 2%, yeast extract 0.18%, maltose 0.24% and agar 0.1%). The flasks were shaken at 26 °C for 7 days on a rotary shaker with 7-cm throw at 220 rpm, to obtain a seed culture. The seed culture was used to inoculate forty 500-ml flasks containing 100 ml of Medium-2 (potato dextrose broth 2.4%). These flasks were shaken at 26 °C for 14 days on a rotary shaker with 7-cm throw at 250 rpm.

Extraction and Isolation

[0038] The fermentation broth (3 l) was filtered after the addition of 2 l of ethanol. The filtrate was concentrated to aqueous solution (1 l), which was then extracted 3 times with each of 1 l of n-butanol. The extract was evaporated to afford an oily residue. The oily residue (3.5 g) was applied to a Sephadex LH-20 column (40 x 500 mm, Pharmacia trademark) and eluted with methanol. The active fractions applied to a YMC-pack ODS AM-343 column (20 x 250 mm, Yamamura trademark) and eluted with methanol - water (15:85 to 70:30) for 45 min at a flow rate of 10 ml/min. The

detection was made by UV absorbance at 220 nm. The eluted peaks showing activity were collected to yield the compounds methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (76.7 mg) and methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate (10.2 mg).

5 **HPLC Analysis**

[0039] Analytical HPLC of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate and methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate was performed using a YMC-pack ODS AM-312 column (6.0 x 150 mm, Yamamura trademark) and eluted with methanol - water (20:80 to 70:30) for 10 min and continually to MeOH for 5 min at a flow rate of 0.8 ml/min. The retention times (min) were methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (7.7) and methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate (10.9).

Characterization

15 [0040] The physico-chemical properties and spectral data of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate and methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate were as follows:

methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate: white amorphous powder; molecular formula C₁₀H₁₃NO₄; LRFAB-MS m/z 212 [M+H]⁺; HRFAB-MS m/z 212.0940 (calcd. for C₁₀H₁₄NO₄, 212.0923); [α]_D²⁴ +20.0 °(c 0.13, MeOH); UV λ_{max} (MeOH) nm (e) 230 (9,500), 270 (5,800); IR γ_{max} (KBr) cm⁻¹ 3325, 1736, 1437, 1309, 1257, 1122, 1089, 1028, 1001, 817, 709. ¹H-NMR (CD₃OD) δ 8.66 (1H, d, J = 1.9 Hz), 8.12 (1H, d, J = 8.1 Hz), 7.99 (1H, dd, J = 8.1 and 1.9 Hz), 4.55 (1H, d, J = 5.9 Hz), 3.96 (3H, s), 3.86 (1H, dq, J = 6.2 and 5.9 Hz), 1.17 (3H, d, J = 6.2 Hz); ¹³C-NMR (CD₃OD) δ 167.39 (s), 150.60 (d), 148.20 (s), 144.80 (s), 138.57 (d), 126.57 (d), 77.49 (d), 72.79 (d), 53.95 (q), 19.95 (q).

20 methyl 5-(1-acetoxy-2-hydroxypropyl)-2-pyridinecarboxylate: white amorphous powder; molecular formula C₁₂H₁₅NO₅; LRFAB-MS m/z 254 [M+H]⁺; HRFAB-MS m/z 254.1051 (calcd. for C₁₂H₁₆NO₅, 254.1028); [α]_D²⁴ +27.1° (c 0.17, MeOH); UV λ_{max} (MeOH) nm (e) 230 (8,200), 270 (4,400); IR γ_{max} (KBr) cm⁻¹ 3465, 1732, 1435, 1370, 1309, 1239, 1120, 1058, 813, 785, 712. ¹H-NMR (CD₃OD) δ 8.67 (1H, d, J = 1.6 Hz), 8.13 (1H, d, J = 8.1 Hz), 8.01 (1H, dd, J = 8.1 and 1.6 Hz), 5.03 (1H, dt, J = 6.2 and 5.4 Hz), 4.82 (1H, d, J = 5.4 Hz), 3.97 (3H, s), 1.95 (3H, s), 1.20 (3H, d, J = 6.2 Hz).

25

30

Example Two

Preparation of 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid

35 [0041] To a solution of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (5 mg) in water (0.1 ml), 1N lithium hydroxide (50 µl) was added at room temperature. After stirring for 1 hour at room temperature, the reaction mixture was neutralized with 1N HCl. The solution was applied to a Diaion HP20 (MitsubishiKasei trademark) column and eluted with methanol-water (1:1) to give 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylic acid: white amorphous powder, molecular formula C₉H₁₁NO₄; LRFAB-MS m/z 196 [M-H]⁻; ¹H-NMR (D₃O) δ 8.74 (1H, d, J = 2.2 Hz), 8.47 (1H, d, J = 8.1 Hz), 8.28 (1H, dd, J = 8.1 and 2.2 Hz), 4.88 (1H, d, J = 4.3 Hz), 4.12 (1H, dq, J = 6.5 and 4.3 Hz), 1.21 (3H, d, J = 6.5 Hz).

Example Three

Preparation of methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate

45 [0042] To a solution of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (6 mg) in pyridine (0.1 ml), acetic anhydride (50 µl) was added at room temperature. After stirring for 1 hour at room temperature, the reaction mixture was evaporated under N₂ gas. The residue was applied to a silica gel plate (Kieselgel GF₂₅₄, 10 x 10 cm, Merck trademark) and developed with chloroform-methanol (9:5) to give methyl 5-(1,2-diacetoxypropyl)-2-pyridinecarboxylate: white amorphous powder; molecular formula C₁₄H₁₇NO₆; LRFAB-MS m/z 296 [M+H]⁺; ¹H-NMR (CDCl₃) δ 8.68 (1H, d, J = 2.2 Hz), 8.16 (1H, d, J = 8.1 Hz), 8.03 (1H, dd, J = 8.1 and 2.2 Hz), 5.95 (1H, d, J = 4.3 Hz), 5.28 (1H, dq, J = 6.5 and 4.3 Hz), 3.97 (3H, s), 2.12 (3H, s), 1.99 (3H, s), 1.18 (3H, d, J = 6.5 Hz).

Example FourPreparation of methyl 5-(1,2-di-p-bromobenzoyloxypropyl)-2-pyridinecarboxylate

- 5 [0043] To a solution of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (4.1 mg) and a catalytic amount of 4-N-N-dimethylaminopyridine in pyridine (1 ml), *p*-bromobenzoyl chloride (10 mg) was added at room temperature. After stirring at 90 °C for 3 days, the reaction mixture was evaporated under N₂ gas. The residue was applied to a silica gel plate (Kieselgel GF₂₅₄, 10 x 10 cm, Merck trademark) and developed with chloroform-methanol (95:5) to give 1.03 mg of methyl 5-(1,2-di-p-bromobenzoyloxypropyl)-2-pyridinecarboxylate: white amorphous powder, molecular formula C₂₄H₁₉Br₂NO₆; LREI-MS m/z 577 [M]⁺. ¹H-NMR (CDCl₃) δ 8.88 (1H, d, J = 2.0 Hz), 8.16 (1H, d, J = 8.4 Hz), 7.94 (1H, dd, J = 8.4 and 2.2 Hz) 7.89 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 8.4 Hz), 7.61 (2H, d, J = 8.4 Hz), 7.58 (2H, d, J = 8.4 Hz), 6.27 (1H, d, J = 4.4 Hz), 5.68 (1H, dq, J = 6.6 and 4.4 Hz), 4.01 (3H, s), 1.41 (3H, d, J = 6.6 Hz)
- 10

Example FivePreparation of 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide

- 15 [0044] A homogeneous mixture of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (70.0mg, 0.33mmol) and a 2.0M solution of ammonia in methanol (Aldrich, 15.0ml, 30.0mmol) was stirred and heated at a bath temperature between 50 and 60 °C in a microreactor overnight. After cooling, the reaction mixture was concentrated in vacuo to give a white solid (64.0mg). This was purified by preparative TLC [Merck Kieselgel 60, Art 1.05744, 0.5mm thick, x2; development: CH₂Cl₂ - MeOH (8:1); elution: CH₂Cl₂ - MOH (3:1), 240ml]. The recovered white solid residue was suspended in THF, and the mixture was filtered through a short pad of Celite. The filter cake was washed with THF. The combined filtrate and washings were concentrated in vacuo to give 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide as a white solid (70.7mg, quantitative): ¹H-NMR (270 MHz) δ(CDCl₃ + DMSO-d₆) 8.57 (d, J=2.2Hz, 1H), 8.11 (d, J=8.1Hz, 1H), 7.89 (dd, J=8.1, 2.1Hz, 1H), 7.86 (br.s, 1H), 6.71 (br.s, 1H), 4.98 (d, J=4.3Hz, 1H), 4.67 (dd, J=4.3, 4.3Hz, 1H), 4.00 (d, J=5.1Hz, 1H), 4.00 ~ 3.87 (m, 1H), 1.07 (d, J=6.2Hz, 3H) ppm; MS m/z 197 (0.83%, M⁺ + 1), 152 (100%).
- 20
- 25

Example SixPreparation of 5-(1,2-dihydroxypropyl)-N,N-dimethyl-2-pyridinecarboxamide

- 30 [0045] A mixture of methyl 5-(1,2-dihydroxypropyl)-2-pyridinecarboxylate (52.0mg, 0.25mmol) and a 2.0M solution of dimethylamine in methanol (Aldrich, 15.0ml, 30.0mmol) was stirred and heated at a bath temperature of 100 °C in a microreactor for four nights. After cooling, the reaction mixture was concentrated in vacuo. The residue (60.3mg) was purified by preparative TLC [Merck Kieselgel 60, Art 1.05744, 0.5mm thick, x2; development: CH₂Cl₂ - MeOH (8:1); elution: CH₂Cl₂ - MOH (3:1), 240ml]. The recovered white solid residue was suspended in THF, and the mixture was filtered through a short pad of Celite. The filter cake was washed with THF. The combined filtrate and washings were concentrated in vacuo to give 5-(1,2-dihydroxypropyl)-N,N-dimethyl-2-pyridinecarboxamide as a white solid (45.2mg, 80.6%): ¹H-NMR (270 MHz) δ(CDCl₃) 8.41 (d, J=1.8Hz, 1H), 7.76 (dd, J=7.9, 1.8Hz, 1H), 7.52 (d, J=7.9Hz, 1H), 4.86 (d, J=3.7Hz, 1H), 4.11 ~ 3.97 (m, 1H), 3.80 (br.s, 1H), 3.13 (s, 3H), 3.04 (s, 3H), 2.68 (br.s, 1H), 1.15 (d, J=6.6Hz, 3H) ppm; MS m/z: 225 (7.9%, M⁺ + 1), 224 (50.9%, M⁺), 153 (100%).
- 35
- 40
- 45

Example SevenPreparation of 5-(1,2-dihydroxypropyl)-2-pyridinecarbonitrile

- 50 [0046] To a solution of 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide (29.5 mg, 0.142 mmol) in DMF (2 ml) were added 2-methoxypropene (41 ml, 0.425 mmol) and p-toluenesulfonic acid monohydrate (4.9 mg, 0.0283 mmol) at room temperature. After stirring at room temperature for 70 min, the mixture was basified with NaHCO₃. The mixture was diluted with ethyl acetate (30 ml), washed with water (20 ml x 2), and dried over Na₂SO₄. After the solvent was evaporated in vacuo, the oily residue was purified by preparative TLC [acetone/hexane (1/2, v/v)] to afford 16.4 mg (49%) of 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide as a white solid: ¹H-NMR (270 MHz, CDCl₃) δ 8.49 (1H, d, J=1.8 Hz), 8.20 (1 H, d, J=8.1 Hz), 7.84 (1H, brs), 7.80 (1H, dd, J=1.8 and 8.1 Hz), 5.89 (1H, br s), 5.27 (1H, d, J=7.0 Hz), 4.66 (1 H, quint, J=6.5 Hz), 1.66 and 1.49 (each 3 H, 2 s), 0.82 (3 H, d, J=6.5 Hz) ppm.
- 55
- [0047] To a stirred solution of 5-(2,2,5-trimethyl-1,3-dioxolan-4-yl)-2-pyridinecarboxamide (16.4 mg, 0.0695 mmol) in 1,4-dioxane (1 ml) were added pyridine (23 ml, 0.278 mmol) and trifluoroacetic anhydride (20 ml, 0.139 mmol) at

room temperature. After stirring at room temperature for 1 h, the mixture was diluted with ethyl acetate (20 ml), washed with sat. NaHCO_3 (10 ml x 2), dried over Na_2SO_4 , and concentrated in vacuo to give a brown syrup. This was purified by preparative TLC [acetone/hexane (1/4, v/v)] to afford 9.7 mg (64%) of 5-(2,2,5-trimethyl-1,3-dioxolan-4-yl)-2-pyridinecarbonitrile as a solid. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.62 (1 H, d, $J=1.8$ Hz), 7.80 (1 H, dd, $J=1.8$ and 8.1 Hz), 7.70 (1 H, d, $J=8.1$ Hz), 5.29 (1 H, d, $J=7.0$ Hz), 4.67 (1 H, quin, $J=6.6$ Hz), 1.64 and 1.43 (each 3H, 2 s), 0.82 (3 H, d, $J=6.6$ Hz) ppm.

[0048] A mixture of (3) (9.7 mg, 0.0444 mmol) and 80% aq. acetic acid (2 ml) was stirred and heated at 60°C for 2.5 h. The mixture was concentrated in vacuo to give a syrup. This was purified by preparative TLC [methanol/dichloromethane (1/10)] to afford 7.4 mg (94%) of 5-(1,2-dihydroxypropyl)-2-pyridinecarbonitrile. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.68 (1 H, d, $J=2.2$ Hz), 7.91 (1 H, dd, $J=2.2$ and 8.1 Hz), 7.70 (1 H, d, $J=8.1$ Hz), 4.84 (1 H, d, $J=3.7$ Hz), 4.11 (1 H, dt, $J=6.2$, 6.2, and 10.3 Hz), 2.99 (1 H, br s), 2.31 (1 H, br s), 1.06 (3 H, d, $J=6.2$ Hz) ppm.

Example Eight

15 **Preparation of 5-(1,2-di-hydroxypropyl)-2-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridine and 5-(1,2-di-hydroxypropyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine**

[0049] To a solution of 5-(1,2-dihydroxypropyl)-2-pyridinecarboxamide (161 mg, 0.771 mmol) in DMF (6 ml) were added imidazole (1.05 g, 15.4 mmol) and *t*-butylchlorodimethylsilane (1.16 g, 7.71 mmol) at room temperature. After the mixture was stirred and heated at 70°C for 5.5 h, water (2 ml) was added, and the stirring was continued under the same heating conditions for 2 h. The mixture was diluted with ethyl acetate (200 ml), washed with water (100 ml x 4), dried over Na_2SO_4 , and concentrated in vacuo to give a crystalline residue. This was chromatographed on silica gel (20 g). Elution with ethyl acetate/hexane (1/4, v/v) afforded 326 mg (99%) of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-pyridinecarboxamide as a white solid. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.50 (1 H, d, $J=1.8$ Hz), 8.15 (1 H, d, $J=8.1$ Hz), 7.86 (1 H, br s), 7.81 (1 H, dd, $J=2.2$ and 8.1 Hz), 5.89 (1 H, br s), 4.40 (1 H, d, $J=6.6$ Hz), 3.74 (1 H, quint, $J=6.1$ Hz), 1.23 (3 H, d, $J=6.2$ Hz), 0.87 and 0.75 (each 9 H, 2 s), 0.06, -0.11, -0.18, and -0.40 (each 3H, 4 s) ppm.

[0050] To a stirred solution of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-pyridinecarboxamide (326 mg, 0.769 mmol) in 1,4-dioxane (8 ml) were added pyridine (0.25 ml, 3.07 mmol) and trifluoroacetic anhydride (0.22 ml, 1.54 mmol) at room temperature. After stirring at room temperature for 0.5 h, the mixture was diluted with ethyl acetate (100 ml), washed with sat. NaHCO_3 (50 ml x 2), dried over Na_2SO_4 , and concentrated in vacuo to give an oily residue. This was chromatographed on silica gel (30 g). Elution with ethyl acetate/hexane (1/15, v/v) afforded 264 mg of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-pyridinecarbonitrile as a solid. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.65 (1 H, d, $J=1.8$ Hz), 7.80 (1 H, dd, $J=1.8$ and 7.7 Hz), 7.65 (1 H, d, $J=7.7$ Hz), 4.39 (1 H, d, $J=6.6$ Hz), 3.72 (1 H, quint, $J=6.2$ Hz), 1.22 (3 H, d, $J=6.2$ Hz), 0.88 and 0.75 (each 9 H, 2 s), 0.07, -0.08, -0.18, and -0.38 (each 3 H, 4 s) ppm.

[0051] To a solution of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-pyridinecarbonitrile (191 mg, 0.468 mmol) in toluene (4 ml) were added NaN_3 (122 mg, 1.87 mmol) and tributyltin chloride (0.51 ml, 1.87 mmol) at room temperature. The stirring was continued with heating at reflux for 27 h. After the mixture was diluted with toluene (2 ml), 1M NaOH (2.4 ml) and MeI (0.6 ml, 9.37 mmol) were added at room temperature. After stirring at room temperature for 3 h, the mixture was diluted with ethyl acetate (100 ml), washed with water (50 ml x 3), dried over Na_2SO_4 , and concentrated in vacuo to give an oily residue. This was purified by preparative TLC [acetone/hexane (1/5, v/v)] to afford 149 mg (68%) of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridine. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.64 (1 H, d, $J=1.8$ Hz), 8.31 (1 H, d, $J=8.4$ Hz), 7.88 (1 H, dd, $J=1.8$ and 8.4 Hz), 4.58 (3 H, s), 4.42 (1 H, d, $J=7.0$ Hz), 3.77 (1 H, quint, $J=6.2$ Hz), 1.26 (3 H, d, $J=6.2$ Hz), 0.90 (and 0.76 (each 9 H, 2 s), 0.09, -0.07, -0.15, and -0.37 (each 3 H, 4 s) ppm; and 63 mg (29%) of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.72 (1 H, d, $J=1.8$ Hz), 8.19 (1 H, d, $J=8.1$ Hz), 7.82 (1 H, dd, $J=2.2$ and 8.1 Hz), 4.45 (3 H, s), 4.41 (1 H, d, $J=6.6$ Hz), 3.79 (1 H, quint, $J=6.2$ Hz), 1.23 (3 H, d, $J=6.2$ Hz), 0.88 and 0.75 (each 9 H, 2 s), 0.07, -0.09, -0.17, and -0.36 (each 3 H, 4 s) ppm.

[0052] To a solution of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridine (149 mg, 0.320 mmol) in THF (4 ml) were added acetic acid (73 ml, 1.28 mmol) and 1M tetrabutylammonium fluoride (TBAF) (1.3 ml, 1.28 mmol) at room temperature. After stirring for 2.5 h, the mixture was concentrated in vacuo to give a syrupy residue. This was purified by preparative TLC [acetone/hexane (1/1, v/v)] to give 42 mg (56%) of 5-(1,2-dihydroxypropyl)-2-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridine. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.68 (1 H, d, $J=1.8$ Hz), 8.19 (1 H, d, $J=8.1$ Hz), 7.93 (1 H, dd, $J=2.0$ and 8.2 Hz), 4.85 (1 H, d, $J=3.7$ Hz), 4.47 (3 H, s), 4.19-4.11 (1 H, m), 3.99 (1 H, br s), 3.27 (1 H, br s), 1.09 (3 H, d, $J=6.2$ Hz) ppm.

[0053] To a solution of 5-[1,2-di-((1-(*tert*-butyl)-1,1-dimethylsilyloxy)propyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine (76.1 mg, 0.164 mmol) in THF (3 ml) were added acetic acid (38 ml, 0.656 mmol) and 1M TBAF (0.7 ml, 0.656 mmol) at room temperature. After stirring at room temperature for 2 h, the mixture was concentrated in vacuo to give a syrupy residue. This was purified by preparative TLC [acetone/hexane (1/1, v/v)] to give 24 mg (63%) of 5-(1,2-di-


hydroxypropyl)-2-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridine. $^1\text{H-NMR}$ (270MHz, CDCl_3) δ 8.69 (1H, d, $J=2.0\text{ Hz}$), 8.14 (1H, d, $J=8.1\text{ Hz}$), 7.89 (1H, dd, $J=2.0$ and 8.1 Hz), 4.85 (1H, d, $J=3.7\text{ Hz}$), 4.44 (3H, s), 4.17-4.08 (1H, m), 3.83 (1H, br s), 3.13 (1H, br s), 1.07 (3H, d, $J=6.2\text{ Hz}$) ppm.

[0054] The chemical structure of the compounds prepared in the examples are summarized in the following Table.

5

TABLE

10



15

20

25

30


35

40

45

50

Example Number	R ¹	R ²	R ³
1	H	H	CH ₃ -O-C(O)-
1	CH ₃ C(O)-	H	CH ₃ -O-C(O)-
2	H	H	COOH
3	CH ₃ C(O)-	CH ₃ C(O)-	CH ₃ -O-C(O)-
4			CH ₃ -O-C(O)-
5	H	H	CONH ₂
6	H	H	CON(CH ₃) ₂
7	H	H	CN
8	H	H	
8	H	H	



(I)

- 10 or a pharmaceutically acceptable salt thereof, wherein R¹ and R² are independently H, C₂-C₆ acyl or halo-substituted benzoyl, and R³ is -C(O)O-C₁-C₆ alkyl, C(O)OH, CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole, with the proviso that when R² is acetyl and R³ is methoxycarbonyl, R¹ is not H, and that when R³ is CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole, R¹ and R² are H.
- 15 2. A compound according to claim 1, wherein R³ is -C(O)O-C₁-C₆ alkyl or C(O)OH, with the proviso that when R² is acetyl and R³ is methoxycarbonyl, R¹ is not H
- 20 3. A compound according to claim 2, said compound being one of the following:
- 25 a compound of formula (I) wherein R¹ and R² are H, and R³ is methoxycarbonyl,
a compound of formula (I) wherein R¹ is acetyl, R² is H, and R³ is methoxycarbonyl,
a compound of formula (I) wherein R¹ and R² are H, and R³ is C(O)OH,
a compound of formula (I) wherein R¹ and R² are acetyl, and R³ is methoxycarbonyl; and
a compound of formula (I) wherein R¹ and R² are p-bromobenzoyl, and R³ is methoxycarbonyl.
- 30 4. A compound according to claim 3, said compound being one of the following:
- 35 a compound of formula (I) wherein R¹ and R² are H, and R³ is methoxycarbonyl,
a compound of formula (I) wherein R¹ is acetyl, R² is H, and R³ is methoxycarbonyl,
a compound of formula (I) wherein R¹ and R² are H, and R³ is C(O)OH, and
a compound of formula (I) wherein R¹ and R² are acetyl, and R³ is methoxycarbonyl.
- 40 5. A compound according to claim 3, wherein R¹ and R² are H, and R³ is methoxycarbonyl, or R¹ is acetyl, R² is H, and R³ is methoxycarbonyl.
- 45 6. A compound according to claim 1, wherein R¹ and R² are H, and R³ is CN, CONH₂, CONHCH₃, CON(CH₃)₂, 1-methyltetrazole or 2-methyltetrazole.
- 50 7. A compound according to claim 6, wherein R³ is CONH₂, CON(CH₃)₂, CN, 1-methyltetrazole or 2-methyltetrazole.
- 55 8. A culture of *Marasmiellus sp.* FERM BP-5735 which is capable of producing a compound according to claim 5.
9. A process for producing a compound according to claim 1, which comprises cultivating a microorganism having the identifying characteristics of *Marasmiellus sp.* FERM BP-5735, or a mutant or recombinant form thereof.
10. A process according to claim 9, which further comprises the subsequent steps of isolating said 5-substituted picolinic acid compounds from the fermentation broth and chemically modifying the isolated compounds.
11. A pharmaceutical composition for use in the treatment of IL-1 and/or TNF mediated diseases and inhibition of IL-1 and/or TNF production, which comprises a compound according to claim 4, or a pharmaceutically acceptable salt thereof in an amount effective in such treatments, and a pharmaceutically acceptable carrier.
12. A method for the treatment of IL-1 and/or TNF mediated diseases of a subject in need of such treatment, which comprises administering to said subject an anti-inflammatory amount of a compound according to claim 4, or a pharmaceutically acceptable salt thereof



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 98 30 3860
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	EP 0 214 004 A (ROUSSEL UCLAF) 11 March 1987 * the whole document * ---	1,11,12	C07D213/79 C07D213/81 C07D213/84 C07D401/04 A61K31/44 C12P17/12
A,D	WO 95 02591 A (SHEDRAKE PETER WILLIAM; ADAMS JERRY LEROY (US); BOEHM JEFFREY CHA) 26 January 1995 * claims; examples * ---	1,11,12	

TECHNICAL FIELDS
SEARCHED (Int.Cl.6)

C07D
A61K
C12P

INCOMPLETE SEARCH

The Search Division considers that the present application, or one or more of its claims, does not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.

Claims searched completely:

Claims searched incompletely:

Claims not searched:

Reason for the limitation of the search:

Although claim 12 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Place of search	Date of completion of the search	Examiner
THE HAGUE	19 February 1999	Bosma, P
CATEGORY OF CITED DOCUMENTS		
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons S : member of the same patent family, corresponding document		

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 8860

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
 The members are as contained in the European Patent Office EPO file.
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-02-1999

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0214004 A	11-03-1987	FR 2585356 A		30-01-1987
		AU 609377 B		02-05-1991
		AU 6050986 A		29-01-1987
		CA 1262903 A		14-11-1989
		DE 3688161 A		06-05-1993
		DE 3688161 T		14-10-1993
		DK 351886 A		26-01-1987
		FI 863040 A,B		26-01-1987
		GR 861924 A		25-11-1986
		JP 1989718 C		08-11-1995
		JP 7010863 B		08-02-1995
		JP 62029585 A		07-02-1987
		KR 9403759 B		30-04-1994
		PT 83064 B		28-02-1989
		SU 1584749 A		07-08-1990
		US 4845105 A		04-07-1989
		US 4988708 A		29-01-1991
-----	-----	-----	-----	-----
WO 9502591 A	26-01-1995	AP 484 A		23-04-1996
		AU 7185098 A		27-08-1998
		AU 694130 B		16-07-1998
		AU 7335494 A		13-02-1995
		BR 9407079 A		27-08-1996
		CA 2167311 A		26-01-1995
		CN 1129447 A		21-08-1996
		CZ 9600119 A		16-10-1996
		EP 0708768 A		01-05-1996
		FI 960177 A		15-01-1996
		HU 75313 A		28-05-1997
		JP 9500137 T		07-01-1997
		NO 960173 A		15-01-1996
		NZ 269457 A		26-08-1998
		PL 312614 A		29-04-1996
		SG 52368 A		28-09-1998
		SK 4796 A		08-01-1997
		US 5593992 A		14-01-1997
		US 5670527 A		23-09-1997
		US 5593991 A		14-01-1997
		US 5663334 A		02-09-1997
		ZA 9405193 A		20-04-1995
-----	-----	-----	-----	-----

For more details about this annex see Official Journal of the European Patent Office, No. 12/82

EPO/1999/0457

